Massachusetts General Hospital Cancer Center
Harvard's largest hospital; leaders in lung cancer targeted therapy, proton therapy, and ctDNA research.
Termeer Center for targeted therapies; ALK/ROS1 and EGFR resistance research; Francis H. Burr Proton Center; Broad Institute affiliation.
- Targeted therapy (lung)
- Proton therapy
- Neuro-oncology
Co-discovered EGFR mutations in lung cancer and pioneered circulating tumour cell technology.
Showed that oncogene-driven lung cancers respond poorly to immunotherapy and led the pivotal RET and ALK inhibitor studies.
Led the first trials of BRAF inhibition in melanoma and chairs the NCI-MATCH precision medicine trial.
Defined EGFR resistance mechanisms in lung cancer and now leads early-detection research including the Sybil AI lung-risk model.
Runs breast medical oncology at MGH and studies the tumour-suppressor biology behind hereditary and triple-negative breast cancer.
Worked out why BRAF inhibitors fail in colorectal cancer and how to combine drugs to overcome it.
Ryan Sullivan is a melanoma trialist and a leading voice on managing immunotherapy side effects.
Showed how radiation, including proton therapy, can be used in liver and pancreatic cancers previously considered unsuitable.